Communiqués Aclaris Therapeutics, Inc.

Actions

ACRS

US00461U1051

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:53:56 24/09/2026			Varia. 5j.	Varia. 1 janv.
5,250 ^USD	-0,19%		-2,31%	+75,25%

01/09	Aclaris Therapeutics, Inc. : Canaccord Genuity réitère son opinion positive sur le titre	ZM
06/08	Aclaris Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

03/09	Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference	AQ
06/08	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)	AQ
06/08	Aclaris: Q2 Earnings Snapshot	AQ
06/08	Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update	AQ
28/05	Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference	AQ
08/05	Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference	AQ
08/05	Aclaris Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Aclaris: Q1 Earnings Snapshot	AQ
07/05	Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update	AQ
28/04	Aclaris Therapeutics : ATI-052 full SAD/MAD results + ATI-2138 update (44ce59)	PU
28/04	Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor	AQ
27/04	Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026	AQ
08/04	Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference	AQ
30/03	Aclaris Therapeutics - Results Presented at 2026 American Academy of Dermatology Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138	AQ
27/03	Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138	AQ
20/03	Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting	AQ
18/03	Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis	AQ
03/03	Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference	AQ
26/02	Aclaris: Q4 Earnings Snapshot	AQ
26/02	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
24/02	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052	AQ
04/02	Aclaris Therapeutics to Participate in Two February Healthcare Conferences	AQ
27/01	Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)	AQ
12/01	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052	AQ
06/01	Aclaris Therapeutics : ATI-052 Interim Phase1a Results January 6, 2026 (4ce773)	PU